

# Special Issue

## HIV Vaccine

### Message from the Guest Editor

This Special Issue of Vaccines on the “HIV vaccine” aims to highlight the unprecedented challenges and the advances that have been made in HIV-1 vaccine field since the RV144 trial. The issue will include research articles, reviews, and short communications on topics including, but not limited to, novel approaches to elicit protective innate, humoral, and cellular responses; the induction of neutralizing and non-neutralizing antibodies and their roles in protection; epitope-based and antibody lineage-based HIV-1 vaccine approaches; and advances in vaccine vectors and adjuvants. The issue will also highlight the unique challenges associated with HIV-1 vaccine development including the high mutability, extreme glycosylation, and poor immunogenicity of HIV-1, the lack of a validated animal model that can fully recapitulate the infection and pathogenesis of HIV in humans, and the lack of definitive correlates of vaccine protection. Thus, this issue will showcase the incredible achievements made in the HIV-1 vaccine field in the last decade.

### Guest Editor

Dr. Chitra Upadhyay

Department of Medicine, Division of Infectious Diseases, Icahn School of Medicine at Mount Sinai, One Gustave L. Levy Place, Box 1090, New York, NY 10029E, USA

### Deadline for manuscript submissions

closed (28 February 2021)



## Vaccines

an Open Access Journal  
by MDPI

Impact Factor 3.4  
CiteScore 9.9  
Indexed in PubMed



[mdpi.com/si/32374](https://mdpi.com/si/32374)

*Vaccines*  
Editorial Office  
MDPI, Grosspeteranlage 5  
4052 Basel, Switzerland  
Tel: +41 61 683 77 34  
[vaccines@mdpi.com](mailto:vaccines@mdpi.com)

[mdpi.com/journal/  
vaccines](https://mdpi.com/journal/vaccines)





# Vaccines

---

an Open Access Journal  
by MDPI

---

Impact Factor 3.4  
CiteScore 9.9  
Indexed in PubMed



[mdpi.com/journal/  
vaccines](https://mdpi.com/journal/vaccines)



## About the Journal

### Message from the Editor-in-Chief

*Vaccines* (ISSN 2076-393X) has had a 6-year history of publishing peer-reviewed state of the art research that advances the knowledge of immunology in human disease protection. Immunotherapeutics, prophylactic vaccines, immunomodulators, adjuvants and the global differences in regulatory affairs are some of the highlights of the research published that have shaped global health. Our open access policy allows all researchers and interested parties to immediately scrutinize the rigorous evidence our publications have to offer. We are proud to present the work and perspectives of many to contribute to future decisions concerning human health.

---

### Editor-in-Chief

Prof. Dr. Ralph A. Tripp

Department of Infectious Diseases, College of Veterinary Medicine,  
University of Georgia, Athens, GA 30602-7387, USA

---

### Author Benefits

#### High Visibility:

indexed within Scopus, SCIE (Web of Science), PubMed, PMC, Embase, CAPIus / SciFinder, and other databases.

#### Journal Rank:

JCR - Q2 (Medicine, Research and Experimental) /  
CiteScore - Q1 (Pharmacology (medical))

#### Rapid Publication:

manuscripts are peer-reviewed and a first decision is provided to authors approximately 19.6 days after submission; acceptance to publication is undertaken in 2.8 days (median values for papers published in this journal in the first half of 2025).